Rodman & Renshaw 17th Annual Global Investment Conference
Date: Thursday, September 10, 2015 Time: 10:00-10:25 AM ET Location: St. Regis Hotel, New York, NY Room: Library (2nd Floor)Webcast: http://wsw.com/webcast/rrshq25/bcli
The webcast may be accessed through the above link during the presentation and for 90 day afterwards.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, including the current randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.